Date: 2012-10-26
Type of information: Licensing agreement
Compound: SGLT2 Inhibitor “CSG452” - tofoglifozin
Company: Chugai Pharmaceutical (Japan) Kowa Company (Japan) Sanofi (France)
Therapeutic area: Metabolic diseases
Type agreement: licensing
co-development
Action mechanism: SGLT2 inhibitor. CSG452 is an inhibitor of sodium-glucose cotransporter 2 (SGLT2), created by Chugai. CSG452 lowers blood glucose by inhibiting glucose reabsorption in the kidney and inducing excretion of excess blood glucose into urine. Currently, Chugai is conducting phase III clinical trial in Japan to evaluate its efficacy and safety for the target indication of type 2 diabetes. This compound has a unique mechanism of action which does not rely on insulin, and in addition to improving both fasting plasma glucose and postprandial glucose, it has low risk of inducing hypoglycemia and has a clear effect of body weight reduction1. It is expected that it will become an emerging oral anti-diabetic.
Disease: type 2 diabetes
Details: Chugai Pharmaceutical, Kowa and Sanofi have entered into license agreements for Chugai’s original compound SGLT2 inhibitor “CSG452” for which Chugai is currently conducting clinical development for type 2 diabetes. Under the agreement, the three companies, Chugai, Kowa and Sanofi will co-develop the compound, and Kowa and Sanofi will file the application for marketing authorization under their own brand names, while Chugai will manufacture the products for supply to the two companies.
Financial terms: Under the terms of the agreements, Chugai will receive milestone payments from Kowa and Sanofi.
Latest news:
